Coeptis Therapeutics Files S-1/A Amendment

TL;DR

Coeptis Therapeutics S-1/A filed Feb 7, 2025. Zero revenue for 9 months ending Sep 30, 2024. Check financials.

AI Summary

Coeptis Therapeutics Holdings, Inc. filed an S-1/A amendment on February 7, 2025, detailing its financial performance. For the nine months ended September 30, 2024, the company reported $0 in revenue. This filing also includes financial data from previous periods, such as December 31, 2023, and September 30, 2023.

Why It Matters

This filing provides an updated look at Coeptis Therapeutics' financial status, crucial for investors assessing the company's current financial health and future prospects.

Risk Assessment

Risk Level: medium — The company has zero revenue for the reported periods, indicating significant financial risk and reliance on future funding or product development.

Key Numbers

• $0 — Revenue (For the nine months ended September 30, 2024, indicating no sales activity.)
• 2024-09-30 — Reporting Period End Date (The latest period for which financial data is presented in the amendment.)
• 2023-12-31 — Fiscal Year End (The company's fiscal year ends on this date.)

Key Players & Entities

• Coeptis Therapeutics Holdings, Inc. (company) — Filer of the S-1/A amendment
• 0001683168-25-000839.txt (document) — Accession number for the filing
• 20250207 (date) — Filing date of the amendment
• Bull Horn Holdings Corp. (company) — Former name of Coeptis Therapeutics Holdings, Inc.
• 20181115 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — 9 shares of our common stock, par value $0.0001 per share ("Common Stock"), which inclu
• $20,000,000 — kholders. However, we may receive up to $20,000,000 aggregate gross proceeds from sales of
• $10.78 — ted sales price of our Common Stock was $10.78 per share. We are an "emerging growth
• $570,000 — ed above, we paid Deverra approximately $570,000 in cash, issued to Deverra 4,000,000 sh
• $16.27 billion — ma market size in these 8 countries was $16.27 billion in 2019 and is expected to increase mod

Filing Documents

• coeptis_s1a1.htm (S-1/A) — 2192KB
• coeptis_ex0501.htm (EX-5.1) — 9KB
• coeptis_ex2301.htm (EX-23.1) — 2KB
• coeptis_ex107.htm (EX-FILING FEES) — 10KB
• image_004.jpg (GRAPHIC) — 12KB
• image_005.jpg (GRAPHIC) — 1KB
• image_006.jpg (GRAPHIC) — 2KB
• image_012.jpg (GRAPHIC) — 11KB
• 0001683168-25-000839.txt ( ) — 6603KB
• coep-20240930.xsd (EX-101.SCH) — 41KB
• coep-20240930_cal.xml (EX-101.CAL) — 57KB
• coep-20240930_def.xml (EX-101.DEF) — 169KB
• coep-20240930_lab.xml (EX-101.LAB) — 309KB
• coep-20240930_pre.xml (EX-101.PRE) — 256KB
• coeptis_s1a1_htm.xml (XML) — 759KB

Use of Proceeds

Use of Proceeds 29 Dividend Policy 29

Managements Discussion and Analysis of Financial Condition and Results of Operations

Managements Discussion and Analysis of Financial Condition and Results of Operations 30

Business

Business 37 Management 43

Executive Compensation

Executive Compensation 50 Certain Relationships and Related Party Transactions 58

Security Ownership of Certain Stockholders and Management

Security Ownership of Certain Stockholders and Management 59 Determination of Offering Price 60 Selling Stockholders 61 Plan of Distribution 63

Description of Capital Stock

Description of Capital Stock 65 Legal Matters 71 Experts 71 Where You Can Find More Information 71 Index to Financial Statements F-1 i About this Prospectus This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the Selling Stockholders (or their pledgees, donees, transferees or other successors-in-interest) may, from time to time, sell or otherwise dispose of the securities described in this prospectus in one or more offerings. We will not receive any proceeds from the sale by such Selling Stockholders of the securities offered by them described in this prospectus. This prospectus provides you with a general description of the shares of Common Stock that the Selling Stockholders may sell or otherwise dispose of. You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. If there is any inconsistency between the information in this prospectus and any prospectus supplement, you should rely on the information provided in the prospectus supplement. Neither we nor the Selling Stockholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement. Neither we nor the Selling Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospect

Forward-looking statements

Forward-looking statements involve a number of risks, uncertainties and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to We may not be able to successfully implement our growth strategy on a timely basis or at all; We may have difficulties managing our anticipated growth, or we may not grow at all; We have a history of losses, we expect to incur losses in the future and we may not be able to achieve or maintain profitability; We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business; We may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates; We may encounter difficulties in managing our growth, which could adversely affect our operations; We need to obtain financing in order to continue our operations; The drug development and approval process is uncertain, time-consuming and expensive; Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for us; Federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any; The regulatory approval process is costly and lengthy, and we may not be able to successfully obtain all required regulatory approvals; Healthcare reform measures could adversely affect our business; iii Protecting and defending against intellectual property claims may have a material adverse effect on our business; If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical a

View Full Filing

View this S-1/A filing on SEC EDGAR